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Abstract
Background: Interstitial lung disease (ILD) associated with clinically amyopathic dermatomyositis (CADM-ILD) is
often refractory and rapidly progressive. Although the anti-melanoma differentiation-associated gene 5 (anti-MDA-5)
antibody is associated with rapidly progressive ILD (RP-ILD), differences in clinical features and prognosis of anti-MDA-5
antibody-positive and -negative CADM-ILD remain unclear.
Methods: To clarify the differences in the clinical features and prognosis between anti-MDA-5 antibody-positive
and -negative cases, we retrospectively reviewed the medical records of patients diagnosed with CADM-ILD
with and without anti-MDA-5 antibody at Kurashiki Central Hospital from January 2005 to September 2014.
Results: Anti-MDA-5 antibody was found in 10 of 16 patients (63 %). The levels of Krebs von den Lungen-6 (KL-6)
and surfactant protein D (SP-D) at the first visit were significantly lower in positive patients than in negative patients,
whereas the levels of aspartate aminotransferase (AST), γ-glutamyl transpeptidase (γ-GTP), and the CD4+/CD8+ ratio in
the bronchoalveolar lavage (BAL) fluid were significantly higher in positive patients than negative patients. Subpleural
ground-glass opacity (GGO) or irregular linear opacity was predominant in positive patients. Peribronchovascular
consolidation was predominant in negative patients. Positive patients had significantly lower survival rates than
negative patients, with all six fatal cases occurring in positive patients who died of refractory ILD within 92 days
from the first visit despite intensive treatment.
Conclusions: There are clear differences in the clinical features and prognosis of anti-MDA-5 antibody-positive
and -negative CADM-ILD. Low serum KL-6 and SP-D levels, high serum AST and γ-GTP levels, high CD4+/CD8+ ratio in
BAL fluid, and predominance of subpleural GGO or irregular linear opacity in HRCT may help to discriminate anti-MDA-5
antibody-positive CADM-ILD with poor prognosis.
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Background
Interstitial lung disease (ILD) is the most common
internal organ manifestation that affects the prognosis of
clinically amyopathic dermatomyositis (CADM), as well as
polymyositis (PM) and dermatomyositis (DM). ILD associ-
ated with CADM (CADM-ILD) is often refractory and
rapidly progressive [1–3], resulting in respiratory failure
with a 6-month survival rate of 40.8–54.5 % [3–5].
Although no standard treatment regimen for CADM-ILD
has been established, intensive treatment with the three-
drug combination of corticosteroid, cyclosporine, and
cyclophosphamide is recommended in the early phase
even if respiratory symptoms are absent or mild [6, 7].
Among patients with CADM, anti-melanoma
differentiation-associated gene 5 (MDA-5) antibodies
are strongly associated with the development of
rapidly progressive ILD (RP-ILD) [8–10]. As MDA-5
plays the critical role in the innate immune defense
against viruses, one hypothesis is that the production of
anti–MDA-5 antibodies is a secondary phenomenon during
virus infection that is associated with the onset of CADM
and RP-ILD. However, to our knowledge, no previous study
has revealed whether the presence or absence of the anti-
MDA-5 antibody affects the clinical manifestation of
CADM-ILD.
In the present study, we retrospectively reviewed
consecutive cases of CADM-ILD to clarify the differences
in the clinical features and prognosis between anti-MDA-5
antibody-positive and -negative cases, and to determine
whether we should separate CADM-ILD by the presence
or absence of anti-MDA-5 antibody.
Methods
Patients and settings
This retrospective study was performed at Kurashiki central
hospital in Kurashiki city, Okayama, Japan. The patients
diagnosed with CADM-ILD at our hospital from January
2005 to September 2014 who had cryopreserved blood
serum before starting treatment were enrolled in this study.
Diagnoses of CADM were made by at least two pulmonol-
ogists and one rheumatologist based on the criteria of
Sontheimer [11]. In addition, patients who exhibited a rash
typical of DM without muscle weakness for less than
6 months and experienced fatal complications such as
acute/subacute ILD were also diagnosed with CADM ac-
cording to Gerami et al.’s criteria [12]. No exclusion criteria
were specified. The Ethics Committee of Kurashiki Central
Hospital approved the study protocol. The Ethics Commit-
tee approved the waiver of each patient’s consent because it
was a retrospective study and high anonymity was secured.
Identification of myositis-specific antibodies
Measurement of myositis-specific antibodies was carried
out by using cryopreserved blood serum before starting
treatment. Serum anti-MDA-5 antibody was measured by
immunoprecipitation using 35S-labeled HeLa cell extract
(Perkin Elmer, Waltham, MA, USA), which was confirmed
by enzyme-linked immunosorbent assay (SRL, Tokyo,
Japan). Other myositis-specific antibodies, including anti-
aminoacyl transfer RNA synthetase (anti-ARS) antibodies,
were measured using the Myositis Profile Euroline antibody
test system (EUROIMMUN, Lubeck, Germany), which
was confirmed by RNA immunoprecipitation (Bio-Rad
Laboratories, Hercules, CA, USA).
Clinical and laboratory findings
Clinical data and laboratory data used in the present study
were retrieved from patient medical records and included
gender, age, smoking history, length of time from onset of
symptoms to first visit, department of the first visit, symp-
toms and physical examination, laboratory data, and
results of bronchoalveolar lavage (BAL) and pulmonary
function tests. BAL was routinely performed under local
anesthesia before starting treatment. The bronchoscope
was wedged into the segmental bronchi. Only samples
with recovery >25 % were used. With regards to pulmon-
ary function test, forced vital capacity and diffusing
capacity for carbon monoxide were measured using same
machine and same method in all patients. Values were
expressed as a percentage of the predicted value.
Radiological findings
All patients underwent high-resolution computed
tomography (HRCT) at the time of diagnosis, and
HRCT findings were reviewed and interpreted by
board-certified pulmonologists and radiologists.
Images were assessed for the dominant craniocaudal/
axial distribution and the dominant shadow [consoli-
dation, ground-glass opacity (GGO), reticulation, or
irregular linear opacity]. The presence of traction
bronchiectasis, cyst, subpleural curve linear shadow,
thickening of the perilymphatic interstitium, emphy-
sema, and loss in lung volume were also assessed.
HRCT protocol and machine was the same for all
included patients at peak tube voltage of 120 kVp and
approximately ≤240 mAs using an automatic exposure
control system (Toshiba Medical Systems, Tochigi,
Japan).
Statistical analysis
Categorical data are presented as numbers (percentages),
while continuous data are presented as medians (inter-
quartile ranges). Fisher’s exact test was used to compare
categorical data, and the Mann–Whitney U test was
used to compare continuous data. Cumulative survival
probabilities were estimated using the Kaplan-Meier
method. The log-rank test was used to compare survival
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From January 2005 to September 2014, we encountered
18 cases of newly diagnosed ILD associated with CADM.
Anti-MDA-5 antibody was measured in 16 cases who had
cryopreserved blood serum before starting treatment.
Anti-MDA-5 antibody was present in 10 patients (positive
group) and absent in 6 patients (negative group). Patients’
characteristics are summarized in Table 1. The median
length of time from onset to first visit was shorter in the
positive group (15.5 vs. 51.0 days, respectively), although
the difference did not reach statistical significance
(p = 0.157). No significant differences were observed
in gender, age, smoking history, or symptoms and signs at
the time of diagnosis between the two groups.
Laboratory data
Laboratory data are summarized in Table 2. Aspartate
aminotransferase (AST) and γ-glutamyl transpeptidase
(γ-GTP) levels were significantly higher (p = 0.0225 and
0.00225, respectively) in the positive group when
compared to the negative group, whereas serum levels of
Krebs von den Lungen-6 (KL-6) and surfactant protein D
(SP-D) at the first visit were significantly lower (p = 0.0160
and 0.00402, respectively) in the positive group than in
the negative group. In the positive group, serum KL-6
gradually increased, whereas serum SP-D remained con-
sistently low 1–4 weeks after treatment initiation (Fig. 1).
In the negative group, one patient each was positive for
anti-Jo1 antibody, anti-PL-12 antibody, anti-OJ antibody,
and anti-PM/Scl-100 antibody. Regarding BAL fluid
analysis, the CD4+/CD8+ ratio was significantly higher in
the positive group than in the negative group (p = 0.0167).
HRCT findings
HRCT findings are shown in Table 3 and Fig. 2. In both
groups, there was a predominance of shadows in the lower
lobe. Subpleural distribution was predominant in the posi-
tive group, whereas peribronchovascular distribution was
predominant in the negative group. In the positive group,
GGO (50 %) was the most commonly observed shadow
followed by irregular linear opacity (30 %). Conversely, in
the negative group, the most common shadow was
consolidation with a significantly higher incidence than in
the positive group (p = 0.00762). While HRCT findings in
the positive and negative group often appeared to be mild,
most were associated with loss of lung volume (90 and
83 %, respectively) or traction bronchiectasis (50 and
67 %, respectively).
Treatments and outcomes
Three-drug combination therapy with corticosteroid, cyclo-
sporine, and cyclophosphamide was the most common
initial treatment in both groups (78 and 83 %, respectively).
The median follow-up period over both groups was
689 days (the data cutoff date was November 9, 2014). In
the present study, six deaths were observed during the
follow-up period; all six cases were positive for anti-MDA-5
antibody and died from refractory ILD within 92 days from
the first visit (median, 30.0 days). Five of these six cases
received intensive initial treatment with corticosteroid,
cyclosporine, and cyclophosphamide. The one remaining
case was refractory to the initial treatment with corticoster-
oid monotherapy, and thus subsequently received cyclo-
sporine and cyclophosphamide.
A comparison of survival curves is shown in Fig. 3.
The anti-MDA-5 antibody-positive group had significantly
lower survival rates than the negative group (p = 0.0252).
Comparison between survivors and non-survivors with
anti-MDA-5 antibody
A comparison between the survivors and non-survivors
in the positive group is shown in Table 4. The length of
time from onset to the first visit was shorter among the
non-survivors than the survivors, although this differ-
ence did not reach statistical significance (p = 0.0666).
Table 1 Summary of clinical characteristics
MDA-5 positive MDA-5 negative p value
(n = 10) (n = 6)
Gender (male/female) 6/4 2/4 0.608
Age 63.0 (58.0–64.8) 71.5 (64.8–73.8) 0.0913
Smoking history 5 (50 %) 2 (33 %) 0.633
Days from onset to first visit 15.5 (11.0–29.8) 51.0 (39.5–77.5) 0.157
Department of the first visit
Respiratory medicine 6 (60 %) 1 (17 %) –
Rheumatology 2 (20 %) 5 (83 %) –
Dermatology 2 (20 %) 0 –
Symptoms and signs at the time of diagnosis
Gottron’s sign/papule 7 (70 %) 5 (83 %) 1.00
Heliotrope eruption 7 (70 %) 1 (17 %) 0.119
V/shawl neck sign 5 (50 %) 2 (33 %) 0.633
Mechanic’s hands 2 (20 %) 2 (33 %) 0.604
Palmar erythema 2 (20 %) 1 (17 %) 1.00
Myalgia 3 (30 %) 0 0.250
Dry cough 5 (50 %) 4 (67 %) 0.633
Dyspnea on exertion 5 (50 %) 5 (83 %) 0.307
Fever 9 (90 %) 3 (50 %) 0.118
Categorical data are presented as numbers (percentages) and were analyzed using
Fisher’s exact test. Continuous data are presented as medians (interquartile ranges)
and were analyzed using the Mann–Whitney U test. A p value of <0.05 was
considered statistically significant
Abbreviation: MDA-5, anti-melanoma differentiation-associated gene 5
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The length of time from onset to treatment initiation
was significantly shorter in non-survivors than in survivors
(p = 0.0381). As for the HRCT findings, the incidence of
GGO was significantly higher among non-survivors than
survivors (p = 0.0480). No significant differences were ob-
served in terms of gender, age, smoking history, PaO2/FiO2
ratio, or BAL fluid analysis results between the two groups.
Discussion
Previous studies, mainly from Asia, have demonstrated
that CADM-ILD often runs an aggressive course [3–5].
On the contrary, Cottin et al. reported good treatment
response and favorable prognosis of CADM-ILD in
France [13]. These results suggest that CADM-ILD in-
cludes a heterogeneous disease population. The present
study demonstrated the four following important clinical
observations. First, serum KL-6 and SP-D at the first
visit were significantly lower in the positive group than
in the negative group. Second, serum AST, γ- GTP, and
CD4+/CD8+ ratio in the BAL fluid were significantly
higher in the positive group than in the negative group.
Third, radiological findings were quite different between
the two groups. Fourth, anti-MDA-5 antibody-positive
cases had significantly lower survival rates than anti-
MDA-5 antibody-negative cases. These clinical differences
imply that anti-MDA-5 antibody-positive and -negative
CADM-ILD should be regarded as separate entities.
The biomarkers ILD, KL-6, and SP-D are reportedly
useful for assessing the prognosis of ILD in PM and DM
[14–16]. However, the usefulness of KL-6 and SP-D in
CADM-ILD has not been fully investigated in previous
research. In the present study, serum levels of KL-6 at
Table 2 Summary of the results of laboratory testing, bronchoalveolar lavage, and pulmonary function test
MDA-5 positive MDA-5 negative p value
(n = 10) (n = 6)
PaO2/FiO2 ratio 296 (274–359) 343 (332–357) 0.689
Laboratory data
White blood cell count (/μL) 5600 (4825–6300) 8150 (5775–10150) 0.573
Aspartate aminotransferase (IU/L) 55.5 (40.5–92.3) 28.5 (23.5–33.5) 0.0225
Alanine aminotransferase (IU/L) 27.0 (17.0–105) 17.0 (16.3–19.3) 0.252
γ-glutamyl transpeptidase (IU/L) 40.5 (23.0–60.5) 15.5 (14.0–22.3) 0.00225
Creatine phosphokinase (IU/L) 184 (90.3–467) 108 (85.8–268) 0.635
Aldolase (U/L) 6.15 (3.58–8.45) 7.50 (4.45–8.45) 0.713
C-reactive protein (mg/dL) 1.28 (0.90–2.94) 0.62 (0.36–3.53) 0.428
Lactate dehydrogenase (IU/L) 368 (302–390) 297 (259–331) 0.0925
Krebs von den Lungen-6 (U/mL) 600 (471–1072) 1700 (1027–3511) 0.0160
Surfactant protein D (ng/dL) 32.5 (22.8–47.6) 181 (98.1–378) 0.00402
Anti-ARS antibody 0 3 (50 %)
Anti Jo-1 0 1 (17 %)
Anti PL-12 0 1 (17 %)
Anti 0 J 0 1 (17 %)
Anti-PM/Scl-100 antibody 0 1 (17 %)
Bronchoalveolar lavage
Total cell count 300 (250–400) 500 (450–700) 0.131
Neutrophil (%) 3.00 (2.50–6.50) 11.0 (8.50–51.5) 0.0855
Eosinophil (%) 1.00 (0.00–1.00) 4.00 (2.00–5.50) 0.284
Lymphocyte (%) 30.0 (24.5–37.0) 41.0 (22.0–42.0) 0.819
Macrophage (%) 60.0 (59.5–70.5) 41.0 (23.0–44.0) 0.0396
CD4+/CD8+ ratio 1.68 (1.13–3.62) 0.420 (0.340–0.490) 0.0167
Lung function test
% Forced vital capacity 79.8 (67.4–90.4) 72.9 (53.4–93.6) 1.00
% Diffusing capacity for carbon monoxide 56.6 (50.2–63.7) 56.9 (54.7–63.0) 0.730
Categorical data are presented as numbers (percentages) and were analyzed using Fisher’s exact test. Continuous data are presented as medians (interquartile
ranges) and were analyzed using the Mann–Whitney U test. A p value of <0.05 was considered statistically significant
Abbreviation: MDA-5, anti-melanoma differentiation-associated gene 5
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the first visit were lower in the positive group than in
the negative group but gradually increased in most of
the cases during the observation period. Although the
cause is not clear, the two following reports may provide
clues for resolving this problem. First, Otsuka et al.
reported that in the early stage of acute exacerbation of
idiopathic pulmonary fibrosis, the elevation in serum
KL-6 mostly occurred after the manifestation of
symptoms and deterioration of HRCT findings and the
other biomarkers of ILD [17]. Second, Sakamoto et al.
reported that the serum levels of KL-6 are significantly
correlated with the extent of traction bronchiectasis
observed in HRCT, which is an indicator of the patho-
logic grade of fibrosis [18]. As anti-MDA-5 antibody-
positive cases tend to progress more rapidly compared
with anti-MDA-5 antibody-negative cases, serum KL-6
Fig. 1 Chronological changes in serum KL-6 and SP-D. a Serum KL-6 levels at first visit and after 1–4 weeks’ treatment initiation in each patient of
the anti-MDA-5 antibody positive (left) and negative groups (right). b Serum SP-D levels at first visit and after 1–4 weeks’ treatment initiation in each
patient of the anti-MDA-5 antibody positive (left) and negative groups (right). Abbreviations: KL-6, Krebs von den Lungen-6; SP-D, surfactant protein D;
MDA-5, anti-melanoma differentiation-associated gene 5
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levels may not yet have increased in anti-MDA-5 antibody-
positive cases at the first medical examination. However,
the higher values of KL-6 in the negative group might be
somewhat affected by 2 subjects who have especially high
KL-6 at first visit, thus we must be careful in interpreting
the results. On the other hand, serum SP-D levels in the
positive group were significantly lower than in the negative
group and remained consistently low during the course of
treatment. In the negative group, serum SP-D levels
decreased after anti-inflammatory treatment in most of the
cases. Several studies have reported that serum SP-D
concentrations are correlated with the extent of alveolitis
(most commonly reflected by increased cellularity in the
alveolar interstitium), but not with the progression of fibro-
sis [19]. Thus, low serum SP-D levels in the positive group
may reflect poor cellularity and progressive fibrotic change,
whereas high serum SP-D levels in the negative group may
reflect relatively abundant cellularity.
As a background to the differences in the KL-6 and
SP-D levels, we believe that immune reactions may differ
in the lung between the two groups. The following two
results support this supposition. 1) Serum levels of AST
and γ-GTP were significantly higher in the positive
group than in the negative group. Elevation of serum hepa-
tobiliary enzymes was reported to be correlated with ILD in
anti-MDA-5 antibody positive DM and CADM patients
[20–22]. It was supposed that anti-MDA-5 antibody is asso-
ciated with alveolar macrophage activation, thereby causing
injury not only to the skin and lung, but also to the liver. 2)
Furthermore, the CD4+/CD8+ ratio in the BAL fluid was
significantly higher in the positive group than in the nega-
tive group. No previous reports have compared the results
of BAL analysis between anti-MDA-5 antibody-positive
and anti-MDA-5 antibody-negative CADM-ILD patients.
Although it remains controversial whether the BAL
lymphocyte subset is useful for clinical diagnosis of ILD,
Suda et al. reported a higher CD4+/CD8+ ratio in patients
with acute/subacute CADM-ILD than chronic CADM-
ILD [23]. Mukae et al. also showed a higher CD4+/CD8+
ratio in the BAL fluid of CADM patients than in those
with classic DM [5]. In addition, Ito et al. found a higher
CD4+/CD8+ ratio in the BAL fluid of DM patients with
RP-ILD than DM patients with chronic ILD [24]. These
results provide further confirmation of our data.
As well as laboratory data, radiological findings were
quite different between the two groups. In the present
study, the most common HRCT pattern in the positive
group was lower subpleural GGO followed by subpleural
irregular linear opacity. Although no previous reports have
clarified HRCT findings of anti-MDA-5 antibody-positive
CADM-ILD, Tanizawa et al. reported that the most
common HRCT pattern in anti-MDA-5 antibody-positive
DM-ILD is lower GGO/consolidation (50 %) followed by
random GGO (33 %) [22]. Irregular linear opacities were
also reported to be typical in CADM-ILD [13, 23, 25]. Intri-
guingly, the prevalence of GGO was significantly higher in
Table 3 Comparison of HRCT findings between patients with and without anti-CADM-antibody
MDA-5 positive MDA-5 negative p value
(n = 10) (n = 6)
Distribution
Upper lobe dominant 1 (10 %) 0 1.00
Lower lobe dominant 9 (90 %) 6 (100 %) 1.00
Peribronchovascular 2 (20 %) 4 (67 %) 0.118
Subpleural 8 (80 %) 2 (33 %) 0.118
Main findings
Consolidation 1 (10 %) 5 (83 %) 0.00762
Ground glass opacity 5 (50 %) 0 0.0934
Reticulation 1 (10 %) 0 1.00
Irregular linear opacity 3 (30 %) 1 (17 %) 1.00
Additional findings
Traction bronchiectasis 5 (50 %) 4 (67 %) 0.633
Cyst 0 1 (17 %) 0.375
Subpleural curve linear shadow 4 (40 %) 3 (50 %) 1.00
Thickening of interlobular septa 2 (20 %) 2 (33 %) 0.604
Emphysema 1 (10 %) 1 (17 %) 1.00
Volume loss 9 (90 %) 5 (83 %) 1.00
Categorical data are presented as numbers (percentages) and were analyzed using Fisher’s exact test
Abbreviations: CADM clinically amyopathic dermatomyositis, HRCT high-resolution computed tomography, MDA-5, anti-melanoma differentiation-associated gene 5
Ikeda et al. BMC Pulmonary Medicine  (2015) 15:159 Page 6 of 10
non-survivors among anti-MDA-5 antibody-positive cases
in the present study. Moreover, in one anti-MDA-5
antibody-positive case with subpleural GGO (as shown in
Fig. 2a), autopsy revealed diffuse alveolar septal thickening
due to organizing fibrosis, airspace organization, and
hyaline membranes, suggesting a diffuse alveolar damage
(DAD) pattern. Although no reports have evaluated the
histopathological findings of treatment-naïve CADM-ILD
with anti-MDA-5 antibody, the pathological findings of
autopsied lung in CADM-ILD with anti-MDA-5 antibody
mostly revealed a DAD pattern [26–28]. Therefore, GGO
in HRCT of anti-MDA-5 antibody-positive CADM-ILD
Fig. 2 High-resolution computed tomography findings. Representative photographs of HRCT scans are presented. a and b initial HRCT scans of
fatal cases positive for anti-MDA-5 antibody showing subpleural GGO. (C) HRCT scans of an anti-MDA-5 antibody-positive patient who survived,
showing subpleural irregular linear opacity. (D) HRCT scans of an anti-MDA-5 antibody-negative patient showing peribronchovascular consolidation.
Abbreviations: GGO, ground-glass opacity; HRCT, high-resolution computed tomography; MDA-5, anti-melanoma differentiation-associated gene 5
Fig. 3 Comparison of survival curves with and without anti-MDA-5 antibody. Cumulative survival probabilities were estimated using the Kaplan–Meier
method. The log-rank test was used to compare survival among patient groups. A p value of <0.05 was considered statistically significant. Abbreviation:
MDA-5, anti-melanoma differentiation-associated gene 5
Ikeda et al. BMC Pulmonary Medicine  (2015) 15:159 Page 7 of 10
may reflect the histopathology of DAD. On the contrary,
peribronchovascular consolidation, which is suggestive of
nonspecific interstitial pneumonia or organizing pneumo-
nia, was most frequently observed in the negative group.
Such CT patterns are generally observed in ILD with classic
DM; in fact, anti-ARS antibody was detected in 50 % of the
negative cases.
These theories on the correlation between HRCT find-
ings and pathological findings are supported by the
differences in treatment response and prognosis between
the two groups. The anti-MDA-5 antibody-positive cases
had significantly lower survival rates than anti-MDA-5
antibody-negative cases; all six fatal cases were positive
for anti-MDA-5 antibody and died from refractory ILD
despite intensive initial treatment, whereas favorable
treatment response and prognosis were observed in the
negative group.
As described above, there are clear differences in the
clinical features and prognosis between anti-MDA-5
antibody-positive and anti-MDA-5 antibody-negative
CADM-ILD; thus, it would be appropriate to separate
CADM-ILD by the presence or absence of anti-MDA-5
antibody. However, only a few medical facilities can
measure anti-MDA-5 antibody levels, and it takes time
to obtain test results; thus, the anti-MDA-5 antibody is
not very helpful for deciding on a treatment policy and
forecasting prognosis. Low levels of serum KL-6 and
SP-D, high levels of serum AST, γ-GTP, and CD4+/CD8+
ratio in BAL fluid, and the predominance of subpleural
GGO or irregular linear opacity in HRCT may provide
Table 4 Comparisons of characteristics and examination findings between anti-MDA-5-positive survivors and non-survivors
Survivors Non-survivors p
value(n = 4) (n = 6)
Gender (male/female) 2/2 4/2 1.00
Age 58.5 (47.8–64.3) 63.0 (59.3–64.5) 0.519
Time
from onset to first visit 29.5 (26.0–50.3) 11.0 (11.0–13.3) 0.0666
from onset to treatment initiation 68.5 (31.5–107) 16.0 (12.8–23.0) 0.0381
Symptoms and signs
Gottron’s sign 2 (50 %) 5 (83 %) 0.500
Heliotrope eruption 2 (50 %) 5 (83 %) 0.500
V/shawl neck sign 1 (25 %) 4 (67 %) 0.524
Mechanic’s hands 0 2 (33 %) 0.467
Palmar erythema 0 2 (33 %) 0.467
Myalgia 2 (50 %) 1 (17 %) 0.500
Cough 4 (100 %) 1 (17 %) 0.0480
Dyspnea on exertion 3 (75 %) 2 (33 %) 0.524
Fever 3 (75 %) 6 (100 %) 0.200
Laboratory data
Aspartate aminotransferase 55.5 (36.8–76.8) 55.5 (41.0–110) 0.762
γ-glutamyl transpeptidase 53.5 (43.5–57.5) 28.0 (23.0–110) 0.914
Krebs von den Lungen-6 1135 (930–1190) 524 (470–626) 0.114
Surfactant protein D 45.3 (23.7–75.8) 32.5 (24.2–40.9) 0.669
Bronchoalveolar lavage
CD4+/CD8+ ratio 3.52 (2.12–4.04) 1.47 (1.20–2.19) 0.857
HRCT findings
Consolidation 1 (25 %) 0 0.400
Ground glass opacity 0 5 (83 %) 0.0480
Reticulation 1 (25 %) 0 1.00
Irregular linear opacity 2 (50 %) 1 (17 %) 0.500
Categorical data are presented as numbers (percentages) and were analyzed using Fisher’s exact test. Continuous data are presented as medians (interquartile
ranges) and were analyzed using the Mann–Whitney U test. A p value of <0.05 was considered statistically significant
Abbreviations: HRCT high-resolution computed tomography, MDA-5, anti-melanoma differentiation-associated gene 5
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clues for discriminating anti-MDA-5 antibody-positive
CADM-ILD with poor prognosis. On the other hand,
the clinical features of anti-MDA-5 antibody-negative
CADM-ILD appear rather similar to those of classical
DM-ILD, and, thus, should probably not be considered as a
distinct clinical entity from classic DM; continuous moni-
toring of muscle and other clinical symptoms is required.
A limitation of the present study is the retrospective
single-center study design. The number of included
patients was small, and the distribution of patients may
have been skewed. Another important limitation to this
study is the risk of multiple comparison testing. Because of
the high number of statistical tests in spite of small number
of the patients, some of these will yield a p-value of <0.05
by chance alone. As for ILD associated with CADM, there
are regional and racial differences in the prevalence of ILD
and the ratio of RP-ILD to the total population of
CADM-ILD [1–4]. Additionally, the prevalence of
anti-MDA-5 antibody is reportedly higher in Eastern Asia
than in Europe or the US, although no previous studies
have made direct comparisons [20, 21, 24, 29–31].
Conclusions
Anti-MDA-5 antibody-positive and anti-MDA-5 antibody-
negative CADM-ILD have clearly different clinico-
radiological features and prognosis, and, thus, it would
be appropriate to separate CADM-ILD by the presence
or absence of anti-MDA-5 antibody. Further investigation
with more cases is required to identify factors associated
with poor prognosis among anti-MDA-5 antibody-positive
CADM-ILD cases.
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